Cargando…
Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals
INTRODUCTION: The extended half-life of dalbavancin justifies a once-a-week dosing schedule and is supposed to favour early discharge. These advantages may therefore compensate for the cost of dalbavancin, but no real-life assessment has been conducted to date. We aimed to assess the real-life budge...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847654/ https://www.ncbi.nlm.nih.gov/pubmed/34913137 http://dx.doi.org/10.1007/s40121-021-00577-6 |
_version_ | 1784652090648297472 |
---|---|
author | Béraud, Guillaume Maupetit, Jean-Claude Darras, Audric Vimont, Alexandre Blachier, Martin |
author_facet | Béraud, Guillaume Maupetit, Jean-Claude Darras, Audric Vimont, Alexandre Blachier, Martin |
author_sort | Béraud, Guillaume |
collection | PubMed |
description | INTRODUCTION: The extended half-life of dalbavancin justifies a once-a-week dosing schedule and is supposed to favour early discharge. These advantages may therefore compensate for the cost of dalbavancin, but no real-life assessment has been conducted to date. We aimed to assess the real-life budget impact of dalbavancin through its impact on the length of stay in French hospitals. METHODS: A multicentre cohort based on the French registry of dalbavancin use in 2019 was compared to the French national discharge summary database. Lengths of stay and budget impact related to the infection type, the time of introduction of dalbavancin, the type of catheter and patient subgroups were assessed. An early switch was defined when dalbavancin was administered as the first or second treatment and within less than 11 days of hospitalization. RESULTS: A total of 179 patients were identified in the registry, and 154 were included in our study. Dalbavancin was mostly used for bone and joint infections (56.0%), infective endocarditis (19.0%) and acute bacterial skin and skin structure infections (6.0%). When compared to the data for similar patients in the national database, the length of stay was almost always shorter for patients treated with dalbavancin (up to a reduction of 13 days). The budget impact for dalbavancin was heterogeneous but frequently generated savings (up to 2257.0 €). Early switching (within less than 11 days) was associated with savings (or lesser costs), with even greater benefits within 7 days of hospitalization. Patients who required a deep venous catheter as well as the most severe patients benefited the most from dalbavancin. CONCLUSION: Our study confirms that dalbavancin is associated with early discharge, which can offset its cost and generate savings. The greatest benefit is achieved with an early switch. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00577-6. |
format | Online Article Text |
id | pubmed-8847654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-88476542022-02-23 Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals Béraud, Guillaume Maupetit, Jean-Claude Darras, Audric Vimont, Alexandre Blachier, Martin Infect Dis Ther Original Research INTRODUCTION: The extended half-life of dalbavancin justifies a once-a-week dosing schedule and is supposed to favour early discharge. These advantages may therefore compensate for the cost of dalbavancin, but no real-life assessment has been conducted to date. We aimed to assess the real-life budget impact of dalbavancin through its impact on the length of stay in French hospitals. METHODS: A multicentre cohort based on the French registry of dalbavancin use in 2019 was compared to the French national discharge summary database. Lengths of stay and budget impact related to the infection type, the time of introduction of dalbavancin, the type of catheter and patient subgroups were assessed. An early switch was defined when dalbavancin was administered as the first or second treatment and within less than 11 days of hospitalization. RESULTS: A total of 179 patients were identified in the registry, and 154 were included in our study. Dalbavancin was mostly used for bone and joint infections (56.0%), infective endocarditis (19.0%) and acute bacterial skin and skin structure infections (6.0%). When compared to the data for similar patients in the national database, the length of stay was almost always shorter for patients treated with dalbavancin (up to a reduction of 13 days). The budget impact for dalbavancin was heterogeneous but frequently generated savings (up to 2257.0 €). Early switching (within less than 11 days) was associated with savings (or lesser costs), with even greater benefits within 7 days of hospitalization. Patients who required a deep venous catheter as well as the most severe patients benefited the most from dalbavancin. CONCLUSION: Our study confirms that dalbavancin is associated with early discharge, which can offset its cost and generate savings. The greatest benefit is achieved with an early switch. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00577-6. Springer Healthcare 2021-12-15 2022-02 /pmc/articles/PMC8847654/ /pubmed/34913137 http://dx.doi.org/10.1007/s40121-021-00577-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Béraud, Guillaume Maupetit, Jean-Claude Darras, Audric Vimont, Alexandre Blachier, Martin Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals |
title | Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals |
title_full | Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals |
title_fullStr | Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals |
title_full_unstemmed | Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals |
title_short | Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals |
title_sort | dalbavancin in real life: economic impact of prescription timing in french hospitals |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847654/ https://www.ncbi.nlm.nih.gov/pubmed/34913137 http://dx.doi.org/10.1007/s40121-021-00577-6 |
work_keys_str_mv | AT beraudguillaume dalbavancininreallifeeconomicimpactofprescriptiontiminginfrenchhospitals AT maupetitjeanclaude dalbavancininreallifeeconomicimpactofprescriptiontiminginfrenchhospitals AT darrasaudric dalbavancininreallifeeconomicimpactofprescriptiontiminginfrenchhospitals AT vimontalexandre dalbavancininreallifeeconomicimpactofprescriptiontiminginfrenchhospitals AT blachiermartin dalbavancininreallifeeconomicimpactofprescriptiontiminginfrenchhospitals |